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IMPORTANCE Radiofrequency denervation is a commonly used treatment for chronic low
back pain, but high-quality evidence for its effectiveness is lacking.
OBJECTIVE To evaluate the effectiveness of radiofrequency denervation added
to a standardized exercise program for patients with chronic low back pain.
DESIGN, SETTING, AND PARTICIPANTS Three pragmaticmulticenter, nonblinded randomized
clinical trials on the effectiveness of minimal interventional treatments for participants with
chronic low back pain (Mint study) were conducted in 16multidisciplinary pain clinics in the
Netherlands. Eligible participants were included between January 1, 2013, and October 24,
2014, and had chronic low back pain, a positive diagnostic block at the facet joints
(facet joint trial, 251 participants), sacroiliac joints (sacroiliac joint trial, 228 participants),
or a combination of facet joints, sacroiliac joints, or intervertebral disks (combination trial,
202 participants) and were unresponsive to conservative care.
INTERVENTIONS All participants received a 3-month standardized exercise program and
psychological support if needed. Participants in the intervention group received
radiofrequency denervation as well. This is usually a 1-time procedure, but themaximum
number of treatments in the trial was 3.
MAIN OUTCOMES ANDMEASURES The primary outcomewas pain intensity (numeric rating
scale, 0-10; whereby 0 indicated no pain and 10 indicated worst pain imaginable) measured
3months after the intervention. The prespecified minimal clinically important difference was
defined as 2 points or more. Final follow-up was at 12 months, ending October 2015.
RESULTS Among 681 participants who were randomized (mean age, 52.2 years; 421 women
[61.8%], mean baseline pain intensity, 7.1), 599 (88%) completed the 3-month follow-up, and
521 (77%) completed the 12-month follow-up. Themean difference in pain intensity between
the radiofrequency denervation and control groups at 3 months was −0.18 (95% CI, −0.76
to 0.40) in the facet joint trial; −0.71 (95% CI, −1.35 to −0.06) in the sacroiliac joint trial;
and −0.99 (95% CI, −1.73 to −0.25) in the combination trial.
CONCLUSIONS AND RELEVANCE In 3 randomized clinical trials of participants with chronic low
back pain originating in the facet joints, sacroiliac joints, or a combination of facet joints,
sacroiliac joints, or intervertebral disks, radiofrequency denervation combined with a
standardized exercise program resulted in either no improvement or no clinically important
improvement in chronic low back pain compared with a standardized exercise program alone.
The findings do not support the use of radiofrequency denervation to treat chronic low back
pain from these sources.
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L ow back pain causes more disability than any othercondition and has major social and economic con-sequences.1-3 In the Netherlands (16.5 million resi-
dents) the cost of low back pain was estimated at €3.5 billion
(US $3.9 billion) in 2007, and the majority of the costs were
attributable to patients with chronic low back pain. In the
United States (326 million residents), the costs of low back
pain have not been recently estimated; however, a study by
Dieleman et al4 evaluated health care spending from 1996 to
2013 in theUnitedStates andestimated thehealth care spend-
ing on low back and neck pain at $87.6 billion.
Potential sources of low back pain of the spinal column
include the facet joints, sacroiliac joints, and intervertebral
disks. These sources of pain were classified as mechanical
low back pain.5,6 Radiofrequency denervation is a commonly
used treatment in pain clinics for chronic low back pain.
In the United States, facet joint or sacroiliac joint interven-
tions in Medicare recipients increased from approximately
425000 interventions in 2000 to 2.2 million interventions in
2013.7 Radiofrequency denervation aims to prevent the con-
duction of nociceptive impulses through the use of an elec-
tric current that damages the pain-conducting nerve. The
effectiveness of radiofrequency denervation has not been
consistently demonstrated. However, there is consensus
among anesthesiologists that minimal interventional proce-
dures such as radiofrequency denervation are effective for
patients with mechanical low back pain.5 Systematic reviews
and multidisciplinary clinical guidelines concluded that
there is evidence of very low to moderate quality supporting
the effectiveness of radiofrequency denervation in clinical
practice for patients with chronic low back pain.5,8-10
The aim of this study was to evaluate whether radiofre-
quency denervation in addition to a standardized exercise
program ismore effective than the standardized exercise pro-
gramalone forpatientswithchronicmechanical lowbackpain.
Methods
Study Design and Participants
The Cost-Effectiveness of Minimal Interventional Proce-
dures for Patients with Chronic Low Back Pain (Mint)
study11 was an initiative to evaluate minimally invasive
treatments for patients with spinal column–related chronic
low back pain, consisting of 4 trials and an observational
study (participants who did not want to be randomized or
who did not meet the inclusion criteria for the trials were
asked to participate in the observational study, where they
received usual care). The full protocol is available in
Supplement 1. One trial was designed to evaluate radiofre-
quency denervation for pain from the intervertebral disks.
This trial was prematurely terminated because of a lack of
eligible participants. The other 3 trials are presented in this
article: (1) the facet joint trial, (2) the sacroiliac joint trial,
and (3) the combination trial (facet joint, sacroiliac joint, or
the intervertebral disk). The Medical Ethics Committee of
the Erasmus University Medical Centre in Rotterdam
granted ethical approval. Local research governance was
obtained from all participating pain clinics. All participants
gave written informed consent.
In 16 multidisciplinary pain clinics in the Netherlands,
pain specialists consecutively screened participants with
chronic low back pain. Inclusion criteria were pain consid-
ered to be related to the facet joint, sacroiliac joint, or a com-
bination of the facet joint, sacroiliac joint, or intervertebral
disk; aged 18 to 70 years; and no improvement in symptoms
after conservative treatment. Medical history and clinical
examination followed a standard format and were performed
by experienced clinicians to determine the likely source of
the pain. To be considered for a diagnostic sacroiliac joint
block, at least 3 of 6 provocation tests (compression test; dis-
traction test; Flexion, Abduction, and External Rotation
[FABER] test; Gaenslen test; thigh thrust test; Gillett test) had
to have positive results.12,13 Participants with suspected iso-
lated facet joint pain or isolated sacroiliac joint pain received
a diagnostic anesthetic block prior to randomization and
were only randomized if the diagnostic block was positive.
Participants with a suspected combination of sources of pain
were randomized based on participant history and physical
examination prior to receiving the diagnostic blocks.
This choice was made for ethical reasons. It would be unethi-
cal to give participants in the study multiple diagnostic
blocks (ie, a facet joint diagnostic block, a sacroiliac joint
diagnostic block, and a provocative discography) before
treatment. Furthermore, it is common practice in Dutch pain
clinics for participants with chronic low back pain due to
facet joints, sacroiliac joints, or intervertebral disks (based on
history taking and physical examination) to start with 1 diag-
nostic block. If the diagnostic block was positive, the inter-
vention was provided. If the diagnostic block was negative,
then another block was provided. If the second diagnostic
block was positive, the intervention was provided. If the sec-
ond diagnostic block was negative, the clinician provided a
third block. All participants were considered candidates for
intervention based on history taking and physical examina-
tion. For this reason, participants were randomized and
included in the combination trial after history taking and
physical examination, if the pain physician suspected that
the pain originated frommore than 1 source.
Key Points
Question What is the effectiveness of radiofrequency
denervation added to a standardized exercise program for patients
with chronic low back pain?
Findings In 3 randomized clinical trials including 681 participants
with chronic low back pain originating from the facet joints,
sacroiliac joints, or a combination of these or the intervertebral
disks, radiofrequency denervation combinedwith exercise
comparedwith exercise alone resulted in either no significant
difference in pain intensity, or a difference smaller than the
prespecifiedminimal clinically important difference after 3months.
Meaning The study findings do not support the use of
radiofrequency denervation for chronic low back pain originating
from these sources.
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Exclusion criteria for all trialswerepregnancy, severepsy-
chological problems (determined with psychological ques-
tionnaires), involvement in work-related conflicts or claims;
body mass index (BMI; calculated as weight in kilograms di-
vided by height in meters squared) higher than 35; or antico-
agulant drug therapy or coagulopathy.
Diagnostic Blocks
For the facet joints,14 a22-gaugeneedlewas inserted to thepos-
terior primary root of the spinal nerve (medial branch) under
C-arm fluoroscopy. L3-4, L4-5, and L5-6 were selected for di-
agnostic blocks. The lateral imagewas checked to confirm the
correct position of the needle, after which 0.5mL of 2% lido-
caine was injected.
For the sacroiliac joints,14 a 25-gauge needle was inserted
3 mm to 10 mm laterally of the sacral foramina S1-3 under
fluoroscopy. The correct depth of the needle was confirmed
laterally, after which 0.5 mL of 2% lidocaine was injected.
The dorsal ramus of L5 was also blocked as described in
the Spinal Intervention Society guidelines using 0.5 mL of
2% lidocaine.
The blocks were considered positive if the participant re-
ported 50% or more pain reduction within 30 to 90 minutes
after the block.
Thecurrentstandardfordiagnosingdiscogenicpain ispres-
sure-controlled provocative discography using strict criteria
and at least 1 negative control level.15
Randomization andMasking
Participants were randomized using a computerized random
number generator (Alea II, Netherlands Cancer Institute-
Antoni van Leeuwenhoek Hospital), accessed through a
password-protected website and maintained independently.
Randomization was performed at the individual level by
means of block randomization (block size = 4), prestratified
for pain clinic. Participants were allocated (1:1) to receive
either radiofrequency denervation with a standardized exer-
cise program (intervention group) or a standardized exercise
program alone (control group).
Participants and caregivers were not blinded. The Dutch
Ministry of Health,Welfare, and Sport requested a pragmatic
trial in which existing, commonly applied treatment options
would be compared. Data handling, analysis, and interpreta-
tion of results were conducted blind to treatment allocation.
All participants were sequentially assigned unique numbers.
Participants’ expectations and satisfaction16,17 were mea-
sured to evaluate a possible risk of bias due to a nonblinded
study design.
Interventions
Standardized Exercise Program
All participants received aprogrambasedon theDutchphysi-
cal therapy guidelines18 in 1 of 102 participating physical
therapypractices.The8- to 12-hourprograms focusedonqual-
ityofmovementandbehavior, andtookplaceduringa3-month
interventionperiod.Moredetails areavailable in thestudypro-
tocol,which is available in Supplement 1. If necessary, partici-
pants were referred to psychological care.
Radiofrequency Denervation
Within 1 week after the first exercise session the intervention
group received radiofrequencydenervation.The technical de-
tails of the radiofrequency denervation procedures are in-
cluded in the eAppendix in Supplement 2.19-22
Co-Interventions
In both treatment groups, participants were asked to refrain
from co-interventions during the intervention period of 3
months (duration of the standardized exercise program).
Co-interventions that were not allowed included (but were
not limited to) surgery; manual therapy; chiropractic therapy;
a change in current, back pain–related medication; or newly
prescribed medication. Analgesics were not prescribed, but
over-the-counter medication was allowed. Co-interventions
or recurrence of the radiofrequency denervation was allowed
after the intervention period of 3 months. These interven-
tions were recorded. Psychological care was not considered a
co-intervention and was provided when needed to partici-
pants in either treatment group.
Outcomes
The primary outcome was pain intensity, measured on an
11-point numerical rating scale (NRS; a score of 0 indicates no
pain; 10 indicates worst pain imaginable) 3 months after the
intervention.23
Secondary outcomes were global perceived recovery,16
participant satisfaction17 (both measured by the 7-point,
categorical Global Perceived Effect scale; a score of 1 indi-
cates fully recovered; 4 indicates no change; 7 indicates
worse than ever), functional status (measured by Oswestry
Disability Index [ODI]; a score of 0 indicates no restrictions in
daily activities; 100 indicates most restrictions in daily
activities),24 health-related quality of life (measured by the
3-level EuroQol 5D Health Questionnaire [EQ-5D-3L]; a score
of 0 indicates worst imaginable health state; 1 indicates best
imaginable health state),25 general health (measured by
RAND 36-Item Health Survey [Rand-36], a score of 0 indi-
cates lowest general health score; 100 indicates highest gen-
eral health score),26 and chronic pain experiences (measured
by the West Haven-Yale Multidimensional Pain Inventory; a
score of 0 indicates lowest score; 6 indicates highest score).27
Theminimal clinically importantdifference inpain forpar-
ticipantswith chronic lowbackpainwas estimated at 2points
or more of the 10-point NRS, a difference of 20 points on the
100-point ODI, and between 0.09 and 0.28 points on the
EQ-5D-3Lutility score between0and 1.28,29Nominimal clini-
cally important differences are known for the other second-
ary outcomes.
All outcome measures were registered using web-based
questionnaires,whichwere sent at baseline and3-, 6-, 9-, and
12-month follow-up. Pain intensity, global perceived recov-
ery, and health-related quality of life were also assessed at
3-week follow-up and 6-week follow-up.
Sample Size Calculation
A clinically relevant mean difference of 2 points or more on
the NRS28 for pain intensity (SD, 4) was used for the sample
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size calculation. With a power of 0.9, a 2-sided α of .05, and
a correlation of 0.5 for repeated measurements, 85 partici-
pants per group were needed. Anticipating potential study
withdrawal (20%), a minimum of 204 participants per trial
was needed.
Statistical Analyses
Effects were estimated using a maximum likelihood estima-
tion for longitudinal mixed-effects model, under “missing
at random” assumptions, including a term for pain clinic, if
necessary, based on the likelihood ratio test.30 We used a
generalized linear mixed model (logit link) for the post hoc
analysis of treatment response for dichotomized outcomes.
The same multilevel structure was used for both models. All
analyses were conducted in accordance with the intention-
to-treat principle.
Regression coefficients or odds ratios (ORs) with 95% CIs
were calculated; ORs were converted to relative risks (RRs)
using the method of Zhang et al31: RR = OR/[(1 − prevalence
in control group) + (prevalence in control group × OR)].
We adjusted for the outcome parameter at baseline, and age,
sex (self-reported), BMI, education, smoking, marital status,
back pain complaint history, and participant expectations.
The effect of interest was the time × treatment interaction.
Regression coefficients can be interpreted as mean differ-
ences between interventions compared with baseline. Addi-
tionally, we calculated the number needed to treat and the
unadjusted risk differences as absolute differences between
groups. Data were compared between complete and incom-
plete cases to identify possible selective dropout.
Treatment success for the global perceived recovery was
defined as “much recovery” or “complete recovery.” In post
hoc analyses, treatment success in pain reduction was de-
fined as either more than 30% or 2 points reduction or more
on the NRS pain scale.
No adjustments for multiple comparisons were made.
Findings for the secondary outcomes should be interpreted
as exploratory.
In 2 sensitivity analyses, participants marked as partici-
pants who had protocol violations, and participants who re-
ceived radiofrequencydenervationduring follow-upwere ex-
cluded from the analyses. Additionally, data were compared
between complete and incomplete cases. We used MLwiN
software (University of Bristol), version 2.22, for the effects
models (2-sided significance P < .05).
Results
In total, 251 patientswere included in the facet joint trial, 228
patients in the sacroiliac joint trial, and 202 in the combina-
tion trial (Figure 1, Figure 2, and Figure 3). The 681 random-
ized participants had a mean age of 52.2 years, 421 partici-
pants were women (61.8%), and the mean baseline pain
intensitywas 7.1 on theNRS scale. Another 5168patientswere
included in the observational part of Mint study.
Figure 1. Flow of Patients Through Enrollment in the 3 Randomized Clinical Trials
5168 Included in observational studya
2133 Asked to participate in the facet joint trial
1882 Excludedb
1202 Declined participation
52 BMI >35
93 Aged >70 y
258 Negative diagnostic facet joint block
277 Psychological problemsc
251 Randomized
See Figure 2
A
10 592 Potential participants
5424 Patients asked to participate in 1 of 3
trials based on suspected source of pain
2498 Asked to participate in the sacroiliac trial
2270 Excludedb
1666 Declined participation
47 BMI >35
83 Aged >70 y
15 Other
202 Negative diagnostic sacroiliac
joint block
257 Psychological problemsc
228 Randomized
See Figure 2
B
793 Asked to participate in the combination trial
591 Excludedb
298 Psychological problemsc
139 Other
52 BMI >35
102 Aged >70 y
202 Randomized
See Figure 3
C
BMI indicates bodymass index (calculated as weight in kilograms divided by
height in meters squared).
a Observational study was performed alongside randomized clinical trials;
results from the observational study are not reported in this article.
b Participants not eligible for participation due to 1 positive exclusion criterion or
more could be included in the observational study.
c Participants were excluded based on psychological problems, assessed by
validated questionnaires.
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Figure 2. Flow of Patients Through the Facet Joint and Sacroiliac Joint Trials
117 Completed baseline visit
8 Did not complete baseline visit
3 Wrong contact information
4 No response
1 Died
116 Completed baseline visit
10 Did not complete baseline visit
4 Wrong contact information
5 No response
1 Unsure about participating
104 Completed baseline visit
8 Did not complete baseline visit
3 Wrong contact information
4 No response
1 Technical difficulties
109 Completed baseline visit
7 Did not complete baseline visit
2 Wrong contact information
5 No response
108 Completed 3-wk follow-up
17 Did not complete 3-wk follow-up
4 Wrong contact information
4 No response
1 Died
8 No treatment details
101 Completed 3-wk follow-up
25 Did not complete 3-wk follow-up
5 Wrong contact information
9 No response
1 Comorbidity
10 No treatment details
86 Completed 3-wk follow-up
26 Did not complete 3-wk follow-up
2 Wrong contact information
9 No response
3 Technical difficulties
10
2
No treatment details
Withdrewb
94 Completed 3-wk follow-up
22 Did not complete 3-wk follow-up
1 Wrong contact information
7 No response
14 No treatment details
119 Completed 6-wk follow-up
6 Did not complete 6-wk follow-up
2 Wrong contact information
2 No response
1 Died
1 No treatment details
118 Completed 6-wk follow-up
8 Did not complete 6-wk follow-up
1 Wrong contact information
5 No response
1 Comorbidity
1 No treatment details
107 Completed 6-wk follow-up
9 Did not complete 6-wk follow-up
1 Wrong contact information
7 No response
1 No treatment details
95 Completed 6-wk follow-up
17 Did not complete 6-wk follow-up
2 Wrong contact information
6 No response
3 Technical difficulties
3 No treatment details
3 Withdrewb
119 Completed 3-mo follow-up
6 Did not complete 3-mo follow-up
1 No internet
4 No response
1 Died
114 Completed 3-mo follow-up
12 Did not complete 3-mo follow-up
1 Wrong contact information
9 No response
1
1
No treatment details
Comorbidity
88 Completed 3-mo follow-up
24 Did not complete 3-mo follow-up
6 Wrong contact information
9 No response
3
6
Technical difficulties
Withdrewb
110 Completed 3-mo follow-up
6 Did not complete 3-mo follow-up
1 Wrong contact information
5 No response
113 Completed 6-mo follow-up
12 Did not complete 6-mo follow-up
2 Unmotivated
9 No response
1 Died
108 Completed 6-mo follow-up
18 Did not complete 6-mo follow-up
1 Wrong contact information
14 No response
1 Unsatisfied
1 No treatment details
1 Comorbidity
89 Completed 6-mo follow-up
23 Did not complete 6-mo follow-up
3 Wrong contact information
10 No response
3 Technical difficulties
7 Withdrewb
103 Completed 6-mo follow-up
13 Did not complete 6-mo follow-up
2 Wrong contact information
11 No response
103 Completed 12-mo follow-up
22 Did not complete 12-mo follow-up
3 No time
18 No response
1 Died
102 Completed 12-mo follow-up
24 Did not complete 12-mo follow-up
1 Wrong contact information
1 No treatment details
19 No response
2 Unmotivated
1 Comorbidity
77 Completed 12-mo follow-up
35 Did not complete 12-mo follow-up
3 Wrong contact information
19 No response
2 Technical difficulties
11 Withdrewb
101 Completed 12-mo follow-up
15 Did not complete 12-mo follow-up
1 Wrong contact information
12 No response
2 Withdrewb
106 Completed 9-mo follow-up
19 Did not complete 9-mo follow-up
1 Unmotivated
1 No internet
3 No time
13 No response
1 Died
78 Completed 9-mo follow-up
34 Did not complete 9-mo follow-up
3 Wrong contact information
19 No response
2 Technical difficulties
10 Withdrewb
105 Completed 9-mo follow-up
21 Did not complete 9-mo follow-up
1 Wrong contact information
18 No response
1 No treatment details
1 Comorbidity
101 Completed 9-mo follow-up
15 Did not complete 9-mo follow-up
1 Wrong contact information
12 No response
2 Withdrewb
125 Included in intention-to-
treat analysis
126 Included in intention-to-
treat analysis
116 Included in intention-to-
treat analysis
112 Included in intention-to-
treat analysis
116 Randomized to intervention group
110 Received radiofrequency
denervation as randomized
3 Received facet joint
radiofrequencya
3 Did not receive treatment
89 Completed exercise program
21 Did not complete exercise
program
6 Unknown completion
81 Received Palisade
radiofrequency treatment
23 Received cooled
radiofrequency denervation
6 Received SIMPLICITY III
denervation
125 Randomized to intervention group
121 Received radiofrequency
denervation as randomized
1 Did not receive treatment
101 Completed exercise program
18 Did not complete exercise
program
6 Unknown completion
3 Received sacroiliac joint
Palisade radiofrequency
treatmenta
112 Randomized to control group
69 Received exercise program
as randomized
18 Did not complete exercise
program
25 Unknown completion
126 Randomized to control group
92 Received exercise program
as randomized
22 Did not complete exercise
program
12 Unknown completion
Continued From Figure 1
251 Randomized
A
228 Randomized
BFacet joint trial Sacroiliac joint trial
a Participants received RF treatment other than their randomized assignment.
b Study withdrawals were not cumulative.
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Figure 3. Flow of Patients Through the Combination Trial
98 Completed baseline visit
5 Did not complete baseline visit
1 Wrong contact information
2 No response
1 No complaints
1 Comorbidity
89 Completed baseline visit
10 Did not complete baseline visit
3 Wrong contact information
7 No response
77 Completed 3-wk follow-up
26 Did not complete 3-wk follow-up
1 Wrong contact information
4 No response
18 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
56 Completed 3-wk follow-up
43 Did not complete 3-wk follow-up
7 Wrong contact information
7 No response
29 No treatment details
90 Completed 6-wk follow-up
13 Did not complete 6-wk follow-up
1 Wrong contact information
3 No response
6 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
82 Completed 6-wk follow-up
17 Did not complete 6-wk follow-up
3 Wrong contact information
10 No response
4 No treatment details
88 Completed 3-mo follow-up
15 Did not complete 3-mo follow-up
1 Wrong contact information
7 No response
4 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
80 Completed 3-mo follow-up
19 Did not complete 3-mo follow-up
3 Wrong contact information
13 No response
3 No treatment details
85 Completed 6-mo follow-up
18 Did not complete 6-mo follow-up
1 Wrong contact information
11 No response
3 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
75 Completed 6-mo follow-up
24 Did not complete 6-mo follow-up
4 Wrong contact information
17 No response
3 No treatment details
80 Completed 9-mo follow-up
23 Did not complete 9-mo follow-up
3 Wrong contact information
13 No response
4 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
68 Completed 9-mo follow-up
31 Did not complete 9-mo follow-up
4 Wrong contact information
3 No treatment details
24 No response
77 Completed 12-mo follow-up
26 Did not complete 12-mo follow-up
3 Wrong contact information
16 No response
4 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
61 Completed 12-mo follow-up
38 Did not complete 12-mo follow-up
6 Wrong contact information
3 No treatment details
29 No response
103 Included in intention-to-treat analysis 99 Included in intention-to-treat analysis
Continued From Figure 1
202 Randomized
CCombination trial
99 Randomized to control group
71 Received exercise program as randomized
28 Did not complete exercise program
103 Randomized to intervention group
67 Received radiofrequency denervation
as randomized
36 Did not receive radiofrequency denervation
1 Positive diagnostic facet joint block
35 Negative diagnostic joint block
93 Completed exercise program
10 Did not complete exercise program
25 Positive facet joint block
21 Positive sacroiliac joint block
21 Positive facet and sacroiliac joint block
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Facet Joint Trial
Study Participants
Between January 1, 2013, and June 3, 2014 (the inclusion pe-
riod for the facet joint trial), 931 participants received a diag-
nostic facet joint block. Patients with a negative result for the
diagnostic facet joint block (n = 258) were excluded. Patients
with psychological problems (n = 277), older than 70 years
(n = 93), or with a BMI higher than 35 (n = 52) were followed
up in the observational study. The inclusion criteriaweremet
by 251 participants for the facet joint trial and were random-
ized to the intervention group (n = 125) and control group
(n = 126) (Figure 1 and Figure 2).
Baseline characteristics were comparable across groups
(Table 1). However, participants in the intervention grouphad
a first low back pain episode 12 years prior compared with 8
years prior in the control group.
Complete data on pain intensity, functional status, and
global perceived recovery after 3 months was obtained from
233 participants (93%). Complete outcome data on all fol-
low-uppoints during the yearwere obtained from 179partici-
pants (71%). Participantswith completedatawereolder,more
often nonsmokers, were more likely to have a partner, had a
higher BMI, andhad lowbackpain complaints for a longer pe-
riod (eTable 1 in Supplement 2).
Table 1. Baseline Characteristics of ParticipantsWith Chronic LowBack Pain
Characteristicsa
Facet Joint Trial Sacroiliac Joint Trial Combination Trial
Intervention
(n = 125)
Control
(n = 126)
Intervention
(n = 116)
Control
(n = 112)
Intervention
(n = 103)
Control
(n = 99)
Age, mean (SD), y 52.98 (11.48) 52.60 (10.79) 51.58 (10.94) 51.13 (12.22) 50.80 (11.33) 53.31 (10.35)
Women, No. (%) 65 (55.56) 60 (51.72) 87 (74.35) 79 (75.96) 64 (65.31) 66 (74.15)
BMI, mean (SD) 26.77 (5.17) 27.62 (4.27) 26.73 (4.17) 26.76 (4.53) 26.84 (3.82) 26.43 (4.25)
Smoker, No. (%) 34 (29.05) 34 (29.05) 29 (26.61) 31 (29.81) 23 (23.46) 26 (29.21)
Education level, No. (%)b
Low 57 (48.72) 64 (55.17) 59 (54.13) 53 (50.96) 52 (53.06) 43 (48.31)
Moderate 35 (29.99) 34 (29.31) 32 (29.36) 32 (30.76) 33 (33.67) 32 (35.96)
High 21 (17.95) 16 (13.79) 18 (16.51) 18 (17.31) 12 (12.24) 14 (15.73)
Married or living with a
partner, No. (%)
93 (79.49) 98 (84.48) 85 (79.61) 82 (79.61) 66 (67.35) 68 (76.40)
Having a paid job, No. (%) 64 (54.70) 66 (56.80) 66 (60.55) 50 (48.07) 48 (48.97) 44 (48.44)
History of back pain,
median (IQR), mo
Time since first
experience with
low back pain
146.00
(49.75-267.67)
100.33
(36.5-186.30)
97.33
(37.51-228.12)
65.08
(27.08-144.21)
120.58
(37.32-222.04)
97.33
(32.33-192.58)
Time since first
current episode with
low back pain
31.33
(12.17-103.42)
26.73
(10.54-73.00)
30.33
(12.17-76.03)
24.33
(12.17-66.58)
36.50
(12.17-121.67)
32.33
(8.00-97.19)
Origin of back pain, No.
Facet and sacroiliac joint 69 70
Facet and disc 18 18
Sacroiliac joint and disc 6 1
Facet and sacroiliac
joint and disc
3 6
Unknown 7 4
CEQ score, mean (SD)c
Credibility 21.36 (3.92) 19.47 (5.49) 21.36 (4.51) 19.88 (5.31) 20.10 (4.70) 17.07 (5.99)
Expectancy 18.97 (4.59) 17.36 (5.20) 18.75 (4.99) 18.23 (5.31) 16.88 (5.78) 14.38 (6.24)
Pain intensity score in the
past week, mean (SD)d
7.14 (1.38) 7.19 (1.29) 7.17 (1.65) 7.06 (1.43) 7.19 (1.43) 7.43 (1.41)
Functioning score,
mean (SD)e
35.07 (14.66) 34.39 (12.24) 38.07 (14.07) 33.70 (14.43) 39.06 (14.03) 37.20 (13.74)
Quality-of-life score,
mean (SD)f
0.52 (0.26) 0.54 (0.26) 0.50 (0.27) 0.56 (0.27) 0.49 (0.28) 0.52 (0.28)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); CEQ, credibility expectancy questionnaire.
a Results are presented of the 233 participants in the facet joint trial,
207 participants in the sacroiliac joint trial, and 187 participants in the
combination trial who had complete baseline data.
b Education levels: low indicates preschool, primary school, or lower secondary
school; moderate indicates higher secondary school or undergraduate; high
indicates tertiary, university, or postgraduate.
c A higher score indicates more credibility in the effectiveness of treatment or
higher expectations about the treatment (score range, 0-27).
dMeasured by numeric rating scale (score range, 0-10); a higher score indicates
more severe pain intensity.
e Measured by Oswestry Disability Index (score range, 0-100); a higher score
indicates worse functioning.
f Measured by EuroQol-5D (score range, 0-1); a higher score indicates better
quality of life.
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Twelve participants in the control group received radio-
frequency denervation within the first 3 months and were
marked as participants who had protocol violations. Ten par-
ticipants (8%) in the interventiongroupand11participants (9%)
in the control group received psychological care during the
3-month intervention period.
No treatment-related adverse events were reported dur-
ing the 1-year follow-up.
Intention-to-Treat Analyses
The mean difference for the primary outcome pain intensity
at 3 months was −0.18 (95% CI, −0.76 to 0.40). Results on all
other follow-up points are shown in Table 2 and Table 3. The
mean difference for functional status at 3 months was −2.45
(95% CI, −5.53 to 1.03); the RR for global perceived recovery
at 3 months was 1.35 (95% CI, 0.81 to 2.05). Other follow-up
points and secondary outcomes are shown in eTable 2 in
Supplement 2.
Post Hoc Analyses of Treatment Response
No significant differences between the groups were found
when success was defined as more than 30% or 2 points re-
duction or more in pain at 3 months (Table 4).
Sensitivity Analyses
When participants with protocol violations were excluded
from the analysis, the interpretation of the outcomes
remained similar (eTable 3 in Supplement 2). After 3 months
of follow–up, 31 control group participants received radiofre-
quency denervation. The analyses were repeated excluding
participants receiving the intervention after the 3-month
intervention period; this did not alter the results either
(eTable 4 in Supplement 2). The complete case analysis
showed no significant between-group differences for pain
intensity, functional status, and global perceived recovery at
3 months (eTable 5 in Supplement 2).
Sacroiliac Joint Trial
Study Participants
Between January 1, 2013, and July 1, 2014 (the inclusion
period for the sacroiliac joint trial), 832 participants received
a diagnostic sacroiliac joint block. Patientswith a negative re-
sult for the diagnostic sacroiliac joint block (n = 202) were
excluded. Patients with psychological problems (n = 257),
older than 70 years (n = 83), or a BMI higher than 35 (n = 47),
or other reasons for not participating in the trial (n = 15) were
followed up in the observational study. The inclusion criteria
were met by 228 participants for the sacroiliac joint trial and
were randomized to the intervention group (n = 116) and the
control group (n = 112) (Figure 1 and Figure 2).
Baseline characteristics were comparable across groups
(Table 1).However, the first episodeof lowbackpain in the in-
tervention group was 97 months before inclusion compared
with 65 months in the control group.
Table 2. Pain Intensity Score (Primary Outcome)a,b Among ParticipantsWith Chronic LowBack Pain
Overall Effect
Intervention Group,
Mean (95% CI)
Control Group,
Mean (95% CI)
Between-Group Difference,
Mean (95% CI)c P Value
Facet joint trial,
No. of participants
125 126
Overall −0.08 (−0.50 to 0.34) .71
3 wk 5.17 (4.73 to 5.61) 5.92 (5.58 to 6.26) −0.41 (−1.02 to 0.19) .18
6 wk 5.19 (4.76 to 5.61) 5.90 (5.53 to 6.26) −0.38 (−0.96 to 0.20) .20
3 mo 5.01 (4.59 to 5.43) 5.44 (5.03 to 5.85) −0.18 (−0.76 to 0.40) .55
6 mo 4.61 (4.18 to 5.04) 4.84 (4.38 to 5.30) −0.04 (−0.63 to 0.56) .91
9 mo 4.66 (4.20 to 5.00) 4.73 (4.24 to 5.22) 0.19 (−0.41 to 0.80) .53
12 mo 4.49 (4.00 to 4.97) 4.44 (3.94 to 4.94) 0.47 (−0.14 to 1.07) .13
Sacroiliac joint trial,
No. of participants
116 112
Overall −0.40 (−0.83 to 0.03) .07
3 wk 4.96 (4.51 to 5.40) 6.00 (5.59 to 6.41) −0.96 (−1.63 to −0.29) .005
6 wk 5.22 (4.81 to 5.64) 5.69 (5.31 to 6.08) −0.53 (−1.17 to 0.10) .10
3 mo 4.77 (4.31 to 5.24) 5.45 (4.94 to 5.95) −0.71 (−1.35 to −0.06) .03
6 mo 4.50 (4.01 to 4.98) 4.78 (4.24 to 5.31) −0.12 (−0.77 to 0.53) .73
9 mo 5.03 (4.55 to 5.51) 4.97 (4.39 to 5.56) 0.16 (−0.51 to 0.83) .64
12 mo 4.65 (4.16 to 5.13) 4.84 (4.30 to 5.38) −0.07 (−0.74 to 0.60) .83
Combination trial,
No. of participants
103 99
Overall −0.21 (−0.76 to 0.35) .47
3 wk 5.45 (4.95 to 5.95) 6.40 (5.91 to 6.89) −0.65 (−1.47 to 0.17) .12
6 wk 5.37 (4.89 to 5.85) 6.09 (5.65 to 6.52) −0.40 (−1.14 to 0.34) .29
3 mo 4.77 (4.25 to 5.30) 5.94 (5.42 to 6.45) −0.99 (−1.73 to −0.25) .01
6 mo 4.92 (4.39 to 5.44) 4.95 (4.35 to 5.54) 0.33 (−0.53 to 1.09) .39
9 mo 5.01 (4.47 to 5.56) 5.25 (4.65 to 5.86) −0.05 (−0.82 to 0.73) .90
12 mo 4.85 (4.24 to 5.46) 4.38 (3.73 to 5.03) 0.69 (−0.10 to 1.49) .09
Abbreviation: NNT, number needed
to treat.
a Measured by numeric rating scale
(score range, 0-10); a higher score
indicates more severe symptoms.
b The overall effect measures provide
information over the total follow-up
time of 12 mo, instead of the
time × treatment effects.
c Values presented (for mean
differences) are model estimates of
linear mixed-effects models with a
random intercept, and adjusted for
outcome at baseline and age, sex,
bodymass index, education,
smoking, marital status, back pain
complaint history, and participant
expectations. Regression
coefficients can be interpreted as
mean differences between
interventions at a certain follow-up
point compared with baseline.
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Table 3. Secondary Outcomes Among ParticipantsWith Chronic LowBack Paina
Overall Effect
Intervention Group,
Mean (95% CI)
Control Group,
Mean (95% CI)
Between-Group
Difference,
Mean (95% CI)b P Value
Risk Difference
(95% CI) NNT
Functioning Scorec,d
Facet joint trial,
No. of participants
125 126
Overall 0.04 (−3.02 to 3.10) .98
3 mo 26.03 (23.01 to 29.06) 28.67 (26.06 to 31.84) −2.45 (−5.93 to 1.03) .17
6 mo 25.38 (22.45 to 28.30) 27.15 (24.07 to 30.23) −0.60 (−4.13 to 2.92) .74
9 mo 25.74 (22.74 to 28.73) 24.52 (21.49 to 27.54) 2.26 (−1.29 to 5.82) .21
12 mo 24.59 (21.39 to 27.79) 25.04 (21.77 to 28.31) 1.48 (−2.09 to 5.06) .42
Sacroiliac joint trial,
No. of participants
116 112
Overall 0.42 (−2.99 to 3.82) .81
3 mo 27.72 (24.50 to 30.95) 29.09 (25.47 to 2.71) −4.20 (−8.39 to −0.00) .05
6 mo 25.99 (22.91 to 29.05) 24.99 (21.45 to 28.52) 0.07 (−4.16 to 4.30) .97
9 mo 28.40 (25.05 to 31.75) 23.45 (20.00 to 6.91) 4.45 (0.14 to 8.77) .04
12 mo 27.29 (23.89 to 30.69) 24.49 (20.74 to 28.23) 2.11 (−2.25 to 6.47) .34
Combination trial,
No. of participants
103 99
Overall 1.90 (−2.96 to 6.76) .44
3 mo 28.00 (24.65 to 31.35) 33.63 (29.88 to 37.37) −4.66 (−10.21 to 0.89) .10
6 mo 30.24 (26.14 to 34.34) 28.61 (24.80 to 32.43) 4.44 (−1.18 to 0.06) .12
9 mo 30.73 (26.83 to 34.63) 28.70 (24.48 to 32.91) 3.55 (−2.17 to 9.26) .22
12 mo 31.20 (27.20 to 35.20) 24.67 (20.88 to 28.45) 6.44 (0.61 to 12.26) .03
Global Perceived Recoverye
No. With Treatment
Success/Total No. (%)
No. With Treatment
Success/Total No. (%)
Relative Risk
(95% CI)f
P Value Risk Difference
(95% CI)
NNT
Facet joint trial,
No. of participants
125 126
3 wk 32/108 (29.63) 5/101 (4.95) 5.41 (2.29 to 10.34) <.001 24.68 (15.08 to 34.27) 4
6 wk 35/119 (29.41) 11/118 (9.32) 2.71 (1.37 to 4.68) .005 20.09 (10.37 to 29.81) 5
3 mo 43/119 (36.13) 27/114 (23.68) 1.35 (0.81 to 2.05) .24 12.45 (0.81 to 24.09) 8
6 mo 46/113 (40.70) 39/108 (36.11) 1.04 (0.64 to 1.12) .85 4.59 (−8.21 to 17.41) NA
9 mo 41/106 (38.67) 42/105 (40.00) 0.81 (0.48 to 0.57) .35 −1.33 (−14.50 to 11.86) NA
12 mo 44/103 (42.71) 40/102 (39.22) 0.90 (0.55 to 1.33) .65 3.49 (−9.95 to 16.96) NA
Sacroiliac joint trial,
No. of participants
116 112
3 wk 28/94 (29.78) 9/88 (10.23) 2.83 (1.39 to 4.89) .01 19.55 (8.35 to 30.77) 5
6 wk 43/110 (39.09) 10/95 (10.53) 3.71 (2.00 to 5.74) <.001 28.56 (17.55 to 39.58) 4
3 mo 43/110 (39.10) 19/88 (21.59) 1.87 (1.13 to 2.71) .02 17.51 (4.97 to 30.03) 6
6 mo 46/103 (44.66) 29/88 (32.95) 1.26 (0.83 to 1.84) .21 11.71 (−2.03 to 25.44) NA
9 mo 36/101 (35.64) 25/78 (32.05) 1.13 (0.67 to 1.70) .62 3.59 (−10.35 to 17.54) NA
12 mo 49/102 (48.03) 24/76 (31.78) 1.46 (0.92 to 2.02) .10 16.25 (2.20 to 30.72) NA
Combination trial,
No. of participants
103 99
3 wk 17/77 (22.07) 4/56 (7.14) 2.23 (0.73 to 5.52) .15 14.93 (3.48 to 25.40) 6
6 wk 25/90 (27.77) 7/82 (8.54) 2.41 (0.99 to 4.90) .05 19.23 (8.19 to 30.30) 5
3 mo 30/88 (34.09) 13/80 (16.25) 1.99 (0.99 to 3.37) .06 17.84 (5.06 to 30.63) 5
6 mo 30/85 (35.29) 28/75 (37.33) 0.76 (0.39 to 1.30) .36 −2.04 (−16.97 to 12.90) NA
9 mo 29/82 (35.36) 21/68 (30.88) 1.11 (0.57 to 1.82) .73 4.48 (−10.61 to 19.57) NA
12 mo 26/75 (34.66) 22/61 (36.06) 0.91 (0.46 to 1.52) .76 −1.40 (−17.65 to 14.76) NA
Abbreviations: NA, not applicable; NNT, number needed to treat.
a The other secondary outcomes are presented in eTable 2 in Supplement 2.
bValues presented (for mean differences) are model estimates of linear
mixed-effects models with a random intercept, and adjusted for outcome
at baseline and age, sex, bodymass index, education, smoking, marital status,
back pain complaint history, and participant expectations. Regression
coefficients can be interpreted as mean differences between interventions
at a certain follow-up point compared with baseline.
c Measured by Oswestry Disability Index (score range, 0-100); a higher score
indicates worse functioning.
d The overall effect measures provide information over the total follow-up time
of 12 mo, instead of the time × treatment effects.
e Measured by the Global Perceived Effect scale (range, 1-7); a score of 1 to 2
indicates success.
f Relative risk was estimated based on themethod of Zhang et al.31
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Table 4. Successful Treatment Effects for Pain Intensity by Study Among ParticipantsWith Chronic LowBack Pain
Intervention Group,
No.With Treatment
Success/Total No. (%)
Control Group,
No. With Treatment
Success/Total No. (%)
Relative Risk
(95% CI)a P Value
Risk Difference
(95% CI) NNT
Facet Joint Trial
Pain intensity
reduction >30%
3 wk 40/102 (39.22) 27/100 (27.00) 1.33 (0.80 to 1.97) .25 12.22 (−0.65 to 25.08) NA
6 wk 45/112 (40.17) 36/114 (31.57) 1.13 (0.70 to 1.63) .59 8.60 (−3.86 to 21.06) NA
3 mo 52/114 (45.61) 40/111 (36.03) 1.16 (0.76 to 1.60) .46 9.58 (−3.20 to 22.36) NA
6 mo 60/108 (55.56) 53/105 (50.47) 1.02 (0.71 to 1.33) .88 5.09 (−8.31 to 18.47) NA
9 mo 52/102 (50.98) 50/102 (49.02) 1.09 (0.75 to 1.42) .60 1.88 (−11.76 to 15.68) NA
12 mo 47/100 (47.00) 53/99 (53.53) 0.78 (0.50 to 1.09) .16 −6.53 (−20.40 to 7.33) NA
Pain intensity
reduction ≥2 points
3 wk 56/102 (54.90) 44/100 (44.00) 1.17 (0.81 to 1.53) .36 10.90 (−2.81 to 24.61) NA
6 wk 57/112 (50.89) 47/114 (41.23) 1.09 (0.74 to 1.46) .65 9.66 (−3.27 to 22.60) NA
3 mo 64/111 (57.65) 52/111 (46.85) 1.07 (0.75 to 1.39) .68 10.80 (−2.25 to 23.87) NA
6 mo 68/108 (62.96) 61/105 (58.09) 1.00 (0.73 to 1.25) .98 4.84 (−8.25 to 17.98) NA
9 mo 56/102 (54.90) 58/102 (56.86) 0.90 (0.62 to 1.17) .47 −1.96 (−15.59 to 11.66) NA
12 mo 55/100 (55.00) 55/99 (55.56) 0.76 (0.49 to 1.05) .11 −0.56 (−14.37 to 13.26) NA
Sacroiliac Joint Trial
Pain intensity
reduction >30%
3 wk 41/90 (45.56) 16/83 (19.27) 2.35 (1.45 to 3.32) .001 26.29 (12.94 to 39.62) 4
6 wk 43/104 (41.35) 25/91 (27.47) 1.49 (0.94 to 2.18) .08 13.88 (0.69 to 27.05) 7
3 mo 48/105 (45.71) 29/84 (34.52) 1.33 (0.87 to 1.81) .16 11.19 (−2.74 to 25.13) NA
6 mo 50/99 (50.51) 42/85 (49.41) 1.01 (0.69 to 1.34) .94 1.10 (−13.40 to 15.58) NA
9 mo 39/98 (39.79) 33/76 (43.42) 0.88 (0.54 to 1.27) .53 −3.63 (−18.39 to 11.14) NA
12 mo 48/97 (49.48) 31/75 (41.33) 1.15 (0.75 to 1.56) .48 8.15 (−6.79 to 23.09) NA
Pain intensity
reduction ≥2 points
3 wk 56/90 (62.22) 30/83 (36.14) 1.68 (1.25 to 2.05) .002 26.08 (11.68 to 40.47) 4
6 wk 59/104 (56.73) 40/91 (43.95) 1.29 (0.97 to 1.59) .08 12.78 (−1.18 to 26.73) NA
3 mo 62/105 (59.05) 40/84 (47.61) 1.25 (0.94 to 1.52) .11 11.44 (−2.80 to 25.66) NA
6 mo 61/99 (61.61) 47/85 (55.29) 1.12 (0.85 to 1.35) .37 6.32 (−7.94 to 20.59) NA
9 mo 51/98 (52.04) 41/76 (53.95) 0.96 (0.68 to 1.22) .76 −1.91 (−16.85 to 13.04) NA
12 mo 57/97 (58.76) 41/75 (54.67) 1.04 (0.76 to 1.30) .77 4.09 (−10.83 to 19.03) NA
Combination Trial
Pain intensity
reduction >30%
3 wk 23/75 (30.67) 7/48 (14.58) 2.39 (1.08 to 4.16) .03 16.09 (1.64 to 30.53) 6
6 wk 32/88 (36.36) 21/72 (29.17) 1.16 (0.63 to 1.84) .60 7.19 (−7.34 to 21.73) NA
3 mo 43/86 (50.00) 19/72 (26.38) 1.92 (1.19 to 2.65) .01 23.62 (8.94 to 38.28) 4
6 mo 36/82 (43.90) 38/68 (55.88) 0.77 (0.44 to 1.11) .19 −11.98 (−27.94 to 3.98) NA
9 mo 38/81 (46.91) 26/61 (42.62) 1.05 (0.62 to 1.52) .83 4.29 (−12.21 to 20.79) NA
12 mo 37/75 (49.33) 32/56 (57.14) 0.86 (0.52 to 1.21) .47 −7.81 (−25.02 to 9.40) NA
Pain intensity
reduction ≥2 points
3 wk 32/75 (42.67) 12/48 (25.00) 1.67 (0.89 to 2.57) .10 17.67 (1.04 to 34.26) 5
6 wk 44/88 (50.00) 33/72 (45.83) 0.96 (0.58 to 1.37) .83 4.17 (−11.38 to 19.71) NA
3 mo 48/86 (55.81) 28/72 (38.88) 1.32 (0.85 to 1.79) .20 16.93 (1.53 to 32.32) 5
6 mo 49/82 (59.76) 43/68 (63.23) 0.91 (0.59 to 1.19) .54 −3.47 (−19.10 to 12.14) NA
9 mo 48/81 (59.25) 34/61 (55.73) 0.98 (0.62 to 1.31) .91 3.52 (−12.91 to 19.95) NA
12 mo 41/75 (54.67) 37/56 (66.07) 0.80 (0.50 to 1.10) .21 −11.40 (−28.16 to 5.35) NA
Abbreviations: NA, not applicable; NNT, number needed to treat.
a Relative risk was estimated based on themethod of Zhang et al.31
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Complete data on pain intensity, functional status, and
global perceived recovery after 3monthswere obtained from
198 participants (87%). Complete outcome data on all fol-
low-uppoints during the yearwere obtained from 134partici-
pants (59%). The participantswith complete datawere older,
more often nonsmokers, were more likely to have a partner,
and had low back pain complaints for a longer period (eTable
1 in Supplement 2).
Sevenparticipants in the control group received radiofre-
quencydenervationwithin the first 3monthsandweremarked
as participants who had protocol violations. Seven partici-
pants (6%) in the intervention group and 6 participants (5%)
in the control group received psychological care during the
3-month intervention period.
Therewas 1 registered treatment-relatedcomplication (va-
sovagal reaction to treatment).
Intention-to-Treat Analyses
The mean difference for the primary outcome pain intensity
at 3months was −0.71 (95% CI, −1.35 to −0.06). Results on all
other follow-up points are shown in Table 2 and Table 3. The
mean difference for functional status at 3 months was −4.20
(95% CI, −8.39 to −0.002); the RR for global perceived recov-
ery at 3 months was 1.87 (95% CI, 1.13 to 2.71). Other fol-
low-up points and secondary outcomes are shown in eTable
2 in Supplement 2.
Post Hoc Analyses of Treatment Response
No significant differences between the groups were found
when success was defined as more than 30% or 2 points re-
duction or more in pain at 3 months (Table 4).
Sensitivity Analyses
When participants who had protocol violations were
excluded from the analysis, the interpretation of the out-
comes remained similar (eTable 3 in Supplement 2). After
3 months of follow–up, 41 control group participants re-
ceived radiofrequency denervation. Excluding these from the
analysis did not change the long-term results (eTable 4 in
Supplement 2). The complete case analysis showed no sig-
nificant between-group differences for the primary outcomes
at 3 months than participants without complete data (eTable
5 in Supplement 2).
Combination Trial
Study Participants
Between January 1, 2013, andOctober 24, 2014 (the inclusion
period for participants in this trial), 793 participants were eli-
gible for this trial. The inclusion criteriaweremet by 202 par-
ticipants, and those participants were randomly assigned to
the intervention (n = 103) and control group (n = 99). All rea-
sons for exclusions are presented in the flow charts (Figure 1
and Figure 3).
Baseline characteristics were comparable in both groups
(Table 1).
Complete data on pain intensity, functional status, and
global perceived recovery after 3 months were obtained
from 168 participants (83%). Complete data on all follow-up
assessments were obtained from 89 participants (44%) on
the effect measures. Participants with complete data had
low back pain complaints for a longer period, but were simi-
lar for all other demographic characteristics (eTable 1 in
Supplement 2).
Two participants in the control group received radiofre-
quency denervation, and 2 participants did not receive any
treatment. In the intervention group, 11 participants did not
receive or it was unknown if they received the standardized
exercise program. These 14 participantswere consideredpar-
ticipantswhohadprotocol violations. Eight participants (8%)
in the interventiongroupand 10participants (10%) in the con-
trol group receivedpsychological care during the 3-month in-
tervention period.
In the intervention group, 35 participants had negative
results for diagnostic blocks and did not receive radiofre-
quency denervation. These participants were still included
in the intention-to-treat analyses. The diagnostic block had
a positive result for 68 participants, of whom 25 received
facet joint radiofrequency denervation, 21 sacroiliac joint
radiofrequency denervation, 21 received a combination
of radiofrequency denervation treatments (facet and sacro-
iliac joint radiofrequency denervation), and 1 participant did
not receive radiofrequency denervation despite a positive
result for the diagnostic block.
Onecomplicationwasrecordedduring the1-year follow-up
in the intervention group: a hematoma, causing extra pain.
The participant completely recovered.
Intention-to-Treat Analyses
The mean difference for the primary outcome pain intensity
at 3months was −0.99 (95%CI, −1.73 to −0.25). Results on all
other follow-up points are shown in Table 2 and Table 3. The
mean difference for functional status at 3 months was −4.66
(95%CI, −10.21 to 0.89); the RR for global perceived recovery
at 3 months was 1.99 (95% CI, 0.99 to 3.36). Other follow-up
points and secondary outcomes are shown in eTable 2 in
Supplement 2.
Post Hoc Analyses of Treatment Response
When success was defined as 30% pain reduction (RR, 1.92
[95%CI, 1.19 to 2.65]), therewas a statistically significant dif-
ference at 3months favoring the intervention group (Table 4).
Sensitivity Analyses
Excluding participants who had protocol violations from the
analysis slightly increased the contrast between the groups,
as significantly more people in the intervention group recov-
ered based on global perceived recovery after 3 months
(RR, 2.07 [95% CI, 1.02 to 3.43]) (eTable 3 in Supplement 2).
After 3 months follow-up, 31 control group participants
received radiofrequency denervation. The analyses were
repeated without participants receiving the intervention
after the 3-month intervention period; this resulted in only
minor differences (eTable 4 in Supplement 2). The complete-
cases analysis showed no significant between-group differ-
ences for the primary outcomes at 3 months (eTable 5 in
Supplement 2).
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Discussion
In 3 trials, the effects of radiofrequency denervation for par-
ticipants with chronic low back pain due to facet joints, sac-
roiliac joints, or a combination of the facet joints, sacroiliac
joints, or intervertebral disks in addition to a standardized ex-
ercise program were compared with a standardized exercise
program alone. The 2 trials assessing radiofrequency dener-
vation for the sacroiliac joints and a combination of the facet
joints, sacroiliac joints, or intervertebral disks showed a sta-
tistically significant but not clinically important improve-
ment inpain intensity3monthsafter the intervention.Noclini-
cally important or statistically significantdifferencesbetween
the groups were shown in the trial assessing radiofrequency
denervation for facet joint pain. Only small or no effectswere
found for all secondary outcomes.
Basedonthis study, radiofrequencydenervation isnot rec-
ommended and should be performed only in a research set-
ting. Patients with chronic low back pain who show no im-
provement in symptomsafter conservative treatmenthaveno
clear alternative therapies that have been shown to be effec-
tive.Future research regarding thediagnosis and treatment for
lowbackpain inparticipantswithchronic lowbackpain isnec-
essary and should focus on better participant selection (be-
cause there remains a possibility that radiofrequency dener-
vation could be beneficial on a subset of participants) and
improvement of the treatment techniques.
Strengths and Limitations
Strengths of these trials are the large sample sizes and strati-
fied randomization that allowed for well-balanced study
groups, and theuseof outcomemeasures as recommendedby
the core outcome set for lowback pain research.32 In addition
to theprimary timepoint at 3months, a follow-upof 12months
was included.
This studyhas several limitations.First, different radiofre-
quencydenervation techniques (cooled radiofrequencydener-
vation, Palisade, and Simplicity III) were used in the sacroiliac
joint trial.33-36 However, the groups were too small for a sub-
groupanalysis.Second,becausetheaimof thestudywastopro-
vide evidence of the added value of radiofrequency denerva-
tion in a multidisciplinary setting, as done in daily practice,
participants and clinicians were not blinded. Evidence sug-
gests that treatment effects for subjective outcomes may
be overestimated when outcome assessors (ie, participants, if
outcomes are self-reported) are not blinded.37 However, the
magnitude of this bias is unknown. The lack of blinding was a
significant limitation of the trials, and it is possible that radio-
frequency denervation could even be harmful, but the lack of
blindingmay havemade the treatment effect seem null. Also,
theshort-termdifferences inglobalperceivedrecovery for facet
joint and sacroiliac joint radiofrequency denervation in ab-
sence of a difference in functional statusmight be the result of
a nonspecific effect due to the nonblinded study design.
Third,a referencestandard fordiagnosing facet jointor sac-
roiliac joint pain is not available.14 In this pragmatic study, di-
agnostic tests that are commonly applied in clinical practice
were used. Controversy concerning the ideal threshold value
of pain reduction in the diagnostic blocks exists. A 50% cut-
offwasmost frequentlyused inprevious studies38 and inclini-
cal practice. Performing 2 or more independent diagnostic
blocks will decrease the false-positive rate, but increase the
numberof false-negativeblocks.38Furthermore, a clinical trial
showed that multiple blocks are not cost-effective.38
Fourth, thegeneralizabilityof the resultsmightbe reduced
by the largenumberofpeopleexcluded forpsychologicalprob-
lems. In theNetherlands,participantsvisitingapainclinicoften
have long-lasting persistent low back pain. A large number of
theseparticipantshavepsychological problems.Thesepartici-
pants were excluded from this study because in daily practice
theyarenotconsideredcandidates for radiofrequencydenerva-
tion andwill be referred to psychological treatment.
Fifth, in all 3 trials, some control group participants re-
ceived radiofrequency denervation after the 3-month inter-
vention period (25% in the facet joint trial, 35% in sacroiliac
joint trial, and 31% in the combination trial) and some inter-
vention group participants received a second radiofrequency
denervation (8% in the facet joint trial, 17% in the sacroiliac
joint trial, and 15% in the combination trial). This could have
influencedthe long-termoutcomes.However, sensitivityanaly-
ses without these participants showed similar results.
Sixth, in the sacroiliac joint trial, therewas a higher drop-
out in thecontrol group.This couldpotentiallyhavebiased the
long-term results.
Seventh, in the combination trial, not all participants in
the intervention group received radiofrequency denerva-
tion, because they did not respond to the diagnostic block or
provocative discography.
Eighth, more missing data were found in the combina-
tion trial compared with the other 2 trials. This is a potential
limitation, but because of the relatively large number of
dropouts at 12 months, the complete case analysis might also
be biased. Although we did not define differences between
the complete-case analysis and the intention-to-treat analy-
sis using all data, it is possible that completers are different
from noncompleters, which could have biased the results of
the complete-case analyses.
Ninth, we assessed multiple outcomes and made no ad-
justment for multiple comparisons, which could have re-
sulted in some statistically significant findings by chance.
ComparisonWith the Literature
Recent systematic reviews have evaluated the association of
radiofrequency denervation with isolated pain sources and
showed evidence of low to moderate quality for associations
of facet joint radiofrequency with small positive effects on
pain and functional status compared with placebo or steroid
injections.9-11 There is very low tomoderate quality evidence
andconflictingevidence for sacroiliac joint radiofrequencyde-
nervation and radiofrequency denervation in the interverte-
bral disk.5,9-11 In the trials included in these reviews, partici-
pantshadabaselinepain scoreof 1 point lower comparedwith
this trial, and the radiofrequency denervation groups de-
creased more (to 3.3 of 10) than the placebo groups (to 5.0 of
10). In the Mint study, participants in both groups decreased
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in pain, but both groups continued to have a higher pain level
compared with other similar trials.
Conclusions
In 3 randomized clinical trials of participants with chronic
low back pain originating in the facet joints, sacroiliac
joints, or a combination of facet joints, sacroiliac joints, or
intervertebral disks, radiofrequency denervation combined
with a standardized exercise program resulted in either no
improvement or no clinically important improvement in
chronic low back pain compared with a standardized exer-
cise program alone. The findings do not support the use of
radiofrequency denervation to treat chronic low back pain
from these sources.
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